Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

Mesenchymal stem cell-derived apoptotic extracellular vesicles loaded with Prussian blue nanoparticles attenuate severe acute pancreatitis via neutrophil extracellular traps resolution and acinar-ductal metaplasia promot

Xu W., Cai W., Wu J., Hou X., Qi X., Wei Z.

Animal Study on Chronic Inflammation, published in J Nanobiotechnology (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
J Nanobiotechnology (2025)
Reported sample size
—
Source database
Europe PMC
PMID
41449408
PMCID
PMC12755009
DOI
10.1186/s12951-025-03958-y
Citations
1

Abstract (original English)

Nowadays, severe acute pancreatitis (SAP) remains a critical clinical disease with a high mortality rate. Current treatments are mainly supportive, lacking specific therapies targeting the core pathological mechanisms including neutrophil extracellular traps (NETs)-mediated systemic inflammation and progressive acinar cell necrosis, which may lead to many complications. Therefore, in this study, we developed a novel dual-targeting nanodrug delivery system named PBs@CCR2-ApopEVs, combining Prussian blue nanoparticles (PBs) and CCR2-overexpressing mesenchymal stem cell-derived apoptotic extracellular vesicles (ApopEVs). Through the specific binding of CCR2 with numerous CCL2 released by neutrophils in SAP, the PBs@CCR2-ApopEVs can be actively recruited to the pancreatic inflammation site. Then PBs effectively inhibit neutrophil extracellular trap (NETs) formation by suppressing myeloperoxidase and elastase expression, as well as Gasdermin D pathway activation, thereby reducing oxidative stress and inflammatory responses. Simultaneously, we confirmed that MSCs-ApopEVs could activate the p-STAT3/SOX4 pathway to promote acinar-to-ductal metaplasia (ADM) process, enhancing the self-protection ability of acinar cells and reducing necrosis. This dual-approach strategy-targeting anti-inflammatory effects externally while reinforcing cytoprotective mechanisms internally-stands out as a n

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
NeutrophilsMesenchymal Stem CellsAnimalsHumansMicePancreatitisMetaplasiaFerrocyanidesApoptosisMale

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research